Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31317848 | 1.00 | CDK5 (0.42) | CDK5CDK5R1DYRK1ACYP1A1ABL1 | |
| SCHEMBL31317851 | 0.89 | CDK5 (0.50) | CDK5CDK5R1DYRK1ACYP1A1ABL1 | |
| SCHEMBL21812348 | 0.89 | CDK5 (0.50) | CDK5CDK5R1DYRK1ACYP1A1ABL1 | |
| SCHEMBL21812467 | 0.85 | TLR8 (0.47) | CDK5CDK5R1DYRK1ACYP1A1ABL1 | |
| SCHEMBL21812320 | 0.84 | CDK5 (0.49) | CDK5CDK5R1DYRK1ACYP1A1TLR8 | |
| SCHEMBL31317802 | 0.84 | CDK5 (0.49) | CDK5CDK5R1DYRK1ACYP1A1TLR8 | |
| SCHEMBL21812394 | 0.82 | WNT3A (0.47) | CDK5CDK5R1DYRK1ACYP1A1ABL1 | |
| SCHEMBL21812423 | 0.82 | TLR8 (0.55) | CDK5CDK5R1DYRK1ACYP1A1TLR8 | |
| SCHEMBL21812425 | 0.82 | CDK5 (0.53) | CDK5CDK5R1DYRK1ACYP1A1ABL1 | |
| SCHEMBL31317870 | 0.82 | WNT3A (0.47) | CDK5CDK5R1DYRK1ACYP1A1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | claimed |
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | claimed |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2025-01-21 | — | — | US | claimed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | claimed |
| EP-3856736-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2021-08-04 | — | — | EP | claimed |
| CN-112930346-A | Novel compounds as NADPH oxidase inhibitors | 金其尤泰克斯瑞士股份有限公司 | 2021-06-08 | — | — | CN | claimed |
| WO-2020065048-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2020-04-02 | — | — | WO | claimed |
| EP-3628669-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2020-04-01 | — | — | EP | claimed |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | disclosed |
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | disclosed |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3856736-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2021-08-04 | — | — | EP | disclosed |
| CN-112930346-A | Novel compounds as NADPH oxidase inhibitors | 金其尤泰克斯瑞士股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
| WO-2020065048-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2020-04-02 | — | — | WO | disclosed |
| EP-3628669-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628669-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2020-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | NOX1, NOX5, NOX4 | CDK5 536/4885CDK5R1 562/4885DYRK1A 2201/4885 |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CYBB, NOX1, NOX4 | CDK5 1096/4885CDK5R1 750/4885DYRK1A 3745/4885 |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CYBB, NOX1, NOX4 | CDK5 964/4885CDK5R1 523/4885DYRK1A 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.